SCHEMBL3512808

SCHEMBL3512808

N#Cc1cc(C(=O)c2ccccc2)ccc1F

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.66
ABCC9 O60706 1/20 0.52
ABCC8 Q09428 1/20 0.52
KCNJ11 Q14654 1/20 0.52
KCNJ8 Q15842 1/20 0.52
VNN1 O95497 1/20 0.50
ATM Q13315 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
HPGD P15428 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
LMNA P02545 2/20 0.49
ALPG P10696 1/20 0.49
ALDH1A1 P00352 2/20 0.47
SRD5A2 P31213 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
USP2 O75604 1/20 0.45
HTT P42858 1/20 0.45
GRM4 Q14833 1/20 0.45
NPC1 O15118 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15867031 0.91 VNN1 (0.56) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL27536109 0.87 CES2 (0.53) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL27536100 0.86 HSD17B14 (0.63) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL2890266 0.85 CNR2 (0.50) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL3511963 0.83 CNR2 (0.51) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL31391729 0.83 CNR2 (0.51) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL30452559 0.82 CNR2 (0.49) CNR2VNN1L3MBTL1HPGDLMNA
SCHEMBL356343 0.82 CNR2 (0.49) CNR2VNN1L3MBTL1HPGDLMNA
SCHEMBL23708557 0.81 VNN1 (0.52) CNR2ABCC9ABCC8KCNJ11KCNJ8
SCHEMBL4609393 0.80 PBRM1 (0.51) CNR2ABCC9ABCC8KCNJ11KCNJ8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435061-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2025-10-07 US disclosed
EP-4574822-A2 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2025-06-25 EP disclosed
CN-118702672-A Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-09-27 CN disclosed
CN-115335050-B Compounds and compositions for treating skin disorders 卡玛瑞制药有限公司 2024-05-17 CN disclosed
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2024-04-18 US disclosed
US-11807621-B2 Compounds and compositions for use in treating skin disorders KAMARI PHARMA LTD. (IL) 2023-11-07 US disclosed
EP-4096661-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS Kamari Pharma Ltd. (IL) 2022-12-07 EP disclosed
CN-115335050-A Compounds and compositions for treating skin conditions 卡玛瑞制药有限公司 2022-11-11 CN disclosed
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS KAMARI PHARMA LTD. (IL) 2022-10-20 US disclosed
US-20220144813-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2022-05-12 US disclosed
US-20150057291-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-26 US disclosed
US-20150057292-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-02-26 US disclosed
US-20140228351-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-08-14 US disclosed
US-8673893-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-03-18 US disclosed
US-20130018036-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-17 US disclosed
US-8299057-B2 Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-30 US disclosed
US-20100292207-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-11-18 US disclosed
CN-101754956-A Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2010-06-23 CN disclosed
EP-2176231-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2010-04-21 EP disclosed
WO-2009013126-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435061-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 CNR2 2393/4885ABCC9 415/4885ABCC8 320/4885
US-20100292207-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 CNR2 4227/4885ABCC9 1724/4885ABCC8 2100/4885
US-20130018036-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, MAP3K3, MAP3K5 CNR2 4227/4885ABCC9 1724/4885ABCC8 2100/4885
US-20220144813-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 CNR2 4519/4885ABCC9 2056/4885ABCC8 2241/4885
US-20150057292-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 CNR2 4519/4885ABCC9 2056/4885ABCC8 2241/4885
US-20140228351-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 CNR2 4519/4885ABCC9 2056/4885ABCC8 2241/4885
US-20240124413-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 CNR2 2393/4885ABCC9 415/4885ABCC8 320/4885
US-20150057291-A1 SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS MAP3K19, ABL1, MAP3K20 CNR2 4519/4885ABCC9 2056/4885ABCC8 2241/4885
US-11807621-B2 Compounds and compositions for use in treating skin disorders RDX, HAX1, F12 CNR2 2393/4885ABCC9 415/4885ABCC8 320/4885
US-20220332697-A1 COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISORDERS RDX, HAX1, F12 CNR2 2393/4885ABCC9 415/4885ABCC8 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.